Want to see SE:BOUL full AI Analyst Report?
BOUL Stock Chart & Stats
kr3.13
-kr0.06(-1.88%)
―
--
Day’s Range― - ―
52-Week Rangekr2.75 - kr6.64
Previous CloseN/A
VolumeN/A
Average Volume (3M)39.59K
Market Cap
kr123.88M
Enterprise Valuekr351.77
Total Cash (Recent Filing)kr19.60M
Total Debt (Recent Filing)kr227.30M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Oct 23, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding38,833,103
10 Day Avg. Volume77,284
30 Day Avg. Volume39,585
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)1.11
Price to Sales (P/S)0.38
P/FCF Ratio-45.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.25
Revenue Forecast (FY)kr453.10M
Bulls Say, Bears Say
Bulls Say
Improved Cash GenerationPositive operating and free cash flow provide internal funding for operations and investment, despite the small net loss. This is a meaningful improvement from 2025 and several prior periods, although continued consistency is needed to establish durability.
Operating Profitability RecoveryThe return to operating profit indicates that Boule's core hematology business can generate earnings before financing and tax costs. Sustaining this recovery would improve resilience and help offset the company's recent revenue softness.
Recurring Consumables Revenue ModelBoule's installed analyzers can generate recurring demand for reagents, controls, calibrators and services after the initial equipment sale. This creates customer retention and revenue visibility, supporting longer-term economics when the installed base expands.
Bears Say
Declining RevenuePersistent revenue contraction signals weaker demand, market execution or customer investment and limits operating leverage. Even with improved profitability, a shrinking top line can constrain growth, reduce scale benefits and pressure future earnings recovery.
Higher Balance-Sheet LeverageDebt now exceeds equity while equity has declined, reducing financial flexibility and increasing sensitivity to earnings volatility. Greater leverage can restrict investment capacity and make any prolonged weakness in operating performance more difficult to absorb.
Inconsistent Net ProfitabilityThe company has not yet converted its operating recovery into sustainable bottom-line profitability. Continued net losses weaken retained capital and shareholder returns, while also limiting confidence that improved cash generation will persist across business cycles.
Boule Diagnostics AB News
BOUL FAQ
What was Boule Diagnostics AB’s price range in the past 12 months?
Boule Diagnostics AB lowest stock price was kr2.75 and its highest was kr6.64 in the past 12 months.
What is Boule Diagnostics AB’s market cap?
Boule Diagnostics AB’s market cap is kr123.88M.
When is Boule Diagnostics AB’s upcoming earnings report date?
Boule Diagnostics AB’s upcoming earnings report date is Oct 23, 2026 which is in 57 days.
How were Boule Diagnostics AB’s earnings last quarter?
Boule Diagnostics AB released its earnings results on Jul 17, 2026. The company reported -kr0.044 earnings per share for the quarter, missing the consensus estimate of kr0.01 by -kr0.054.
Is Boule Diagnostics AB overvalued?
According to Wall Street analysts Boule Diagnostics AB’s price is currently Undervalued.
Does Boule Diagnostics AB pay dividends?
Boule Diagnostics AB pays a N/A dividend of kr0.389 which represents an annual dividend yield of N/A. See more information on Boule Diagnostics AB dividends here
What is Boule Diagnostics AB’s EPS estimate?
Boule Diagnostics AB’s EPS estimate is -0.02.
How many shares outstanding does Boule Diagnostics AB have?
Boule Diagnostics AB has 38,833,103 shares outstanding.
What happened to Boule Diagnostics AB’s price movement after its last earnings report?
Boule Diagnostics AB reported an EPS of -kr0.044 in its last earnings report, missing expectations of kr0.01. Following the earnings report the stock price went down -8%.
Which hedge fund is a major shareholder of Boule Diagnostics AB?
Currently, no hedge funds are holding shares in SE:BOUL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Boule Diagnostics AB
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, and Medonic brands; and veterinary hematology and clinical chemistry analyzer systems, as well as reagents and panels under the Exigo brand. It serves small and medium-sized hospitals, clinics, laboratories, and veterinary clinics, and other diagnostics firms. The company was founded in 1956 and is headquartered in Spånga, Sweden.